ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 18 of 155 for:    "Huntington disease"

Is Caffeine an Environmental Modifier in Huntington's Disease? (CrEAM-HD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03034122
Recruitment Status : Recruiting
First Posted : January 27, 2017
Last Update Posted : December 22, 2017
Sponsor:
Information provided by (Responsible Party):
University Hospital, Lille

Brief Summary:
The aim of the study is to establish if caffeine consumption is associated with the evolution of the disease in premanifest HD.

Condition or disease
Huntington Disease

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Is Caffeine an Environmental Modifier in Huntington's Disease?
Actual Study Start Date : October 11, 2017
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : October 2021

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Change in striatal volume [ Time Frame: at 2 years ]

Secondary Outcome Measures :
  1. Unified Huntington's Disease Rating Scale (UHDRS) [ Time Frame: at 1 years, at 2 years ]
    measure the change of motor scale for exposure caffeine groups

  2. SDMT -symbol digit modality test [ Time Frame: at 1 years, at 2 years ]
    measure the change of cognitive score for exposure caffeine groups

  3. Stroop test [ Time Frame: at 1 years, at 2 years ]
    measure the change of cognitive score for exposure caffeine groups

  4. PBA (problem behaviors assessment) [ Time Frame: at 1 years, at 2 years ]

    the PBA is a semi structured clinical interview measuring the presence, severity and frequency of 11 key behavioural symptoms.

    measure the change score and subscores for apathy, obsessive-compulsive disorders, irritability, anxiety and depression,


  5. score at Epworth sleepiness scale [ Time Frame: at 1 years, at 2 years ]
    measure the change of sleepiness scale for exposure caffeine groups

  6. MRI [ Time Frame: at 1 years, at 2 years ]
    measure the change of image of the whole brain and other deep gray nuclei atrophy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
premanifest HD subjects
Criteria

Inclusion Criteria:

  • HD mutation carriers (>36 CAG)
  • premanifest (total motor UHDRS < 5)
  • estimated time to diagnosis between 3 and 10 years
  • adults older than 21 years (in order to exclude juvenile patients who begin the disease before 21 years)
  • informed consent signed
  • with a social protection

Exclusion Criteria:

  • MRI contraindication
  • pregnant and lactating women
  • People under guardianship, trusteeship, deprive of freedom

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03034122


Contacts
Contact: Clémence Simonin, MD 0320445962 ext +33 clemence.simonin@chru-lille.fr

Locations
France
Hôpital Roger Salengro, CHRU Recruiting
Lille, France
Principal Investigator: Clémence Simonin, MD         
Sponsors and Collaborators
University Hospital, Lille
Investigators
Principal Investigator: Clémence Simonin, MD University Hospital, Lille

Responsible Party: University Hospital, Lille
ClinicalTrials.gov Identifier: NCT03034122     History of Changes
Other Study ID Numbers: 2015_67
2016-A00892-49 ( Other Identifier: ID-RCB number, ANSM )
First Posted: January 27, 2017    Key Record Dates
Last Update Posted: December 22, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Dementia
Chorea
Dyskinesias
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Neurocognitive Disorders
Mental Disorders
Caffeine
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents